Abivax S.A. (AAVXF) Stock Analysis
Market cap $10.2B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Abivax S.A. (AAVXF) trades at $139.00 with AI Score 51/100 (Grade B). Abivax S.A. is a French biotechnology company focused on discovering and developing therapies for inflammatory diseases, infectious diseases, and cancer. Market cap: $10.2B, Sector: Healthcare.
Price as of Aug 27, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for AAVXF: AAVXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AAVXF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
These figures come from statements filed 13 months ago — the most recent this company has published.
AAVXF: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Abivax S.A. (AAVXF) Healthcare & Pipeline Overview
Abivax S.A. is a French biotech firm specializing in novel therapies for inflammatory and infectious diseases, and cancer, with a primary focus on its lead compound ABX464 currently in Phase II clinical trials. The company operates in a competitive biotech landscape, targeting unmet medical needs with innovative drug candidates.
What Is the Investment Thesis for AAVXF?
Abivax presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful development and commercialization of ABX464, targeting multi-billion dollar markets in ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Positive Phase IIb trial results for ABX464 in inflammatory bowel diseases could serve as a significant catalyst, potentially leading to partnerships or acquisition offers. However, the company's negative profit margin of -3244.0% and reliance on clinical trial outcomes pose substantial risks. The negative beta of -0.38 suggests low correlation with the overall market, but also reflects the company's idiosyncratic risk profile. Investors should closely monitor clinical trial data, regulatory milestones, and the company's cash runway.
Based on FMP financials and quantitative analysis
AAVXF Key Highlights
Market capitalization of $10.2B, reflecting investor expectations for its drug pipeline.
- Gross margin of 100.0%, indicating strong potential profitability if products reach commercialization.
- Negative P/E ratio of -34.01 due to current losses, typical for biotechnology companies in the development stage.
- ABX464 in Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, representing a key value driver.
- Negative profit margin of -3244.0%, highlighting the company's current reliance on funding and future product success.
Who Are AAVXF's Competitors?
AAVXF is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACLX Arcellx, Inc. | $115.07 | +0.02% | $6.73B | — |
| ARWR Arrowhead Pharmaceuticals, Inc. | $89.12 | +0.27% | $12.6B | 305-pillar |
| AXSM Axsome Therapeutics, Inc. | $207.15 | +0.81% | $10.7B | — |
| CRSP CRISPR Therapeutics AG | $59.37 | +0.24% | $5.73B | 449-signal |
| CYTK Cytokinetics, Incorporated | $78.89 | -0.39% | $9.82B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are AAVXF's Key Strengths?
Promising lead drug candidate (ABX464) in Phase II trials.
- Focus on high-growth therapeutic areas.
- Collaborations with reputable research institutions.
- Experienced management team.
What Are AAVXF's Weaknesses?
High cash burn rate and reliance on external funding.
- Clinical trial risks and regulatory hurdles.
- Limited commercialization experience.
- Concentration of pipeline on a few key assets.
What Could Drive AAVXF Stock Higher?
Phase IIb clinical trial results for ABX464 in ulcerative colitis and Crohn's Disease.
- Potential strategic partnerships with larger pharmaceutical companies.
- Advancement of ABX196 in hepatocellular carcinoma clinical trials.
- Expansion into new therapeutic areas and geographic markets.
- Regulatory approvals for its drug candidates.
What Are the Key Risks for AAVXF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials or regulatory setbacks.
- Competition from established pharmaceutical companies.
- Patent challenges and intellectual property disputes.
- High cash burn rate and reliance on external funding.
- Limited commercialization experience.
What Are the Growth Opportunities for AAVXF?
- Expansion into New Therapeutic Areas: Abivax has the opportunity to leverage its drug discovery platform to expand into new therapeutic areas beyond its current focus. This could involve targeting other inflammatory diseases, exploring new oncology indications, or developing therapies for emerging infectious diseases. The market for novel therapeutics is substantial, with significant unmet needs across various disease areas. Success in expanding its pipeline could drive long-term growth and diversification.
- Strategic Partnerships and Collaborations: Abivax can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Partnering with established players can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, creating opportunities for Abivax to leverage its assets and expertise.
- Geographic Expansion: Abivax currently focuses its operations in France. Expanding into new geographic markets, such as the United States and Asia, could significantly increase its market reach and revenue potential. These regions represent large and growing healthcare markets with a high demand for innovative therapies. Successful geographic expansion would require establishing local operations, navigating regulatory requirements, and building relationships with key stakeholders.
- Advancement of ABX196 in Hepatocellular Carcinoma: The development of ABX196, an immune enhancer candidate for the treatment of hepatocellular carcinoma, represents a significant growth opportunity. Hepatocellular carcinoma is a major unmet medical need with a growing incidence worldwide. Positive clinical trial results for ABX196 could lead to regulatory approval and commercialization, generating substantial revenue for Abivax. The company is currently in Phase 1/2 clinical trials for this candidate.
- Development of Therapies for Dengue Fever, Influenza, and RSV: Abivax's research programs targeting Dengue fever, influenza, and respiratory syncytial virus (RSV) offer potential growth opportunities. These infectious diseases represent significant public health challenges with a large global market for effective therapies. Successful development of novel treatments for these diseases could generate substantial revenue and improve public health outcomes. The company is currently in the research phase for these programs.
What Are AAVXF's Competitive Advantages?
- Proprietary drug discovery platform.
- Patent protection for its drug candidates.
- Clinical trial data demonstrating efficacy and safety.
- Strategic partnerships with research institutions.
What Does AAVXF Do?
Abivax S.A., incorporated in 2013 and headquartered in Paris, France, is a biotechnology company dedicated to discovering and developing drugs for the treatment of inflammatory diseases, infectious diseases, and cancer. The company's core focus lies in optimizing therapeutic solutions for conditions with significant unmet medical needs. Abivax's lead product, ABX464, is a promising drug candidate currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn's Disease. Additionally, ABX464 is being evaluated in Phase IIa clinical trials for rheumatoid arthritis and has completed Phase IIa trials for achieving viral remission in HIV patients. Beyond ABX464, Abivax is developing ABX196, an immune enhancer candidate in Phase 1/2 clinical trials for hepatocellular cancer. The company also has research programs targeting Dengue fever, influenza, and respiratory syncytial virus. Abivax has established license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie, underscoring its commitment to collaborative research and development.
What Products and Services Does AAVXF Offer?
- Discovers and develops drugs for inflammatory diseases.
- Focuses on treatments for infectious diseases.
- Develops therapies for various forms of cancer.
- Conducts clinical trials to evaluate drug efficacy and safety.
- Optimizes drug formulations for improved patient outcomes.
- Collaborates with research institutions and universities.
- Seeks regulatory approvals for its drug candidates.
How Does AAVXF Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to demonstrate efficacy and safety.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
What Industry Does AAVXF Operate In?
Abivax operates within the competitive biotechnology industry, characterized by high R&D spending, lengthy clinical trial processes, and stringent regulatory requirements. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Abivax's focus on inflammatory diseases, infectious diseases, and cancer aligns with major market trends. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies.
Who Are AAVXF's Key Customers?
- Pharmaceutical companies seeking to expand their product portfolios.
- Patients suffering from inflammatory diseases, infectious diseases, and cancer.
- Healthcare providers prescribing medications to their patients.
- Research institutions and universities collaborating on drug development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 424 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
Why 51?
This rating comes from our nine-signal model, which produces a score but not a per-factor breakdown. The sector-relative five-pillar model, which explains its own contributions, does not cover this listing yet. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 5 snapshots
| 2026-08-23 | 51 |
| 2026-08-24 | 51 |
| 2026-08-25 | 51 |
| 2026-08-26 | 51 |
| 2026-08-27 | 51 |
What changed?
The score has stayed at 51.
Over the same 4 days the stock moved +0.0%.
Company Profile
Abivax S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Marc de Garidel. AAVXF has traded publicly since 2016.
Key Financial Metrics
Return on assets is -44.7%, showing how much profit it generates from its asset base. A current ratio of 8.25 indicates the company holds enough short-term assets to cover its near-term obligations.
AAVXF Valuation & Market Position
With a $10.2B market cap, Abivax S.A. sits in the large-cap segment of the market. Relative to its peer group, AAVXF's quantitative score of 51/100 is above the peer average of 37/100.
Quarterly Financial Performance: Abivax S.A.
Revenue for Abivax S.A. came in at $2.4M during Q2 FY2025, a 49.7% contraction versus the preceding quarter. The company recorded a net loss of $117.4M, with diluted EPS of $-1.85. Revenue has contracted over three consecutive quarters, which investors in this large-cap Healthcare stock should monitor closely.
Financial Health
Abivax S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 20.30 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Abivax S.A. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 35.7% below estimates on average.
Forward Outlook
Wall Street analysts project Abivax S.A. revenue of about $3.9M for fiscal 2026, with EPS near $-3.37. The estimate reflects 14 contributing analysts.
AAVXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Promising lead drug candidate (ABX464) in Phase II trials.
- Focus on high-growth therapeutic areas.
- Collaborations with reputable research institutions.
- Experienced management team.
Bear Case
- High cash burn rate and reliance on external funding.
- Clinical trial risks and regulatory hurdles.
- Limited commercialization experience.
- Concentration of pipeline on a few key assets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2025 | $2M | -$117M | -$1.85 |
| Q4 FY2024 | $5M | -$110M | -$1.75 |
| Q2 FY2024 | $8M | -$95M | -$1.51 |
Q2 FY2025 · filed 30 Jun 2025 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
AAVXF Latest News
No recent news available for AAVXF.
AAVXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AAVXF.
Price Targets
Wall Street price target analysis for AAVXF.
AAVXF MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. AAVXF scores 51/100 (Grade B): the number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Leadership: Marc de Garidel
CEO
Marc de Garidel has extensive experience in the pharmaceutical industry. Prior to joining Abivax, he held leadership positions at Ipsen, where he served as Chairman and CEO. He also worked at Amgen and Eli Lilly. De Garidel has a strong track record of driving growth and innovation in the pharmaceutical sector. He holds an MBA from INSEAD and a degree in engineering from Ecole Centrale Paris.
Track Record: Under Marc de Garidel's leadership, Abivax has advanced its lead drug candidate, ABX464, through clinical trials and secured strategic partnerships. He has focused on building a strong management team and attracting investment to support the company's growth. His experience in the pharmaceutical industry has been instrumental in guiding Abivax's strategy and execution.
AAVXF OTC Market Information
The OTC Other tier, where AAVXF trades, represents the lowest tier of the OTC market. Companies in this tier may not meet minimum financial standards or have chosen not to provide current information to the market. This tier is distinct from the NYSE or NASDAQ, which have stringent listing requirements regarding financial performance, corporate governance, and trading volume. OTC Other stocks often carry higher risks due to limited information and regulatory oversight compared to exchange-listed securities.
- OTC Tier: OTC Other
- Limited information and disclosure requirements.
- Potential for price manipulation and fraud.
- Higher volatility and lower liquidity.
- Increased risk of delisting or suspension of trading.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings.
- Presence of an experienced management team.
- Patent protection for its drug candidates.
- Collaborations with reputable research institutions.
- Advancement of drug candidates through clinical trials.
- Focus on addressing unmet medical needs.
AAVXF Healthcare Stock FAQ
What does the AI Score mean for AAVXF?
AAVXF holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
What do analysts say about AAVXF stock?
Analyst coverage of AAVXF is limited due to its OTC listing and development stage. Key valuation metrics, such as P/E ratio, are currently negative due to the company's ongoing losses.
What are the key factors to evaluate for AAVXF?
Abivax S.A. (AAVXF) holds an AI score of 51/100 (moderate). However, the company's negative profit margin of -3244.0% and reliance on clinical trial outcomes pose substantial risks. Not financial advice.
How frequently does AAVXF data refresh on this page?
AAVXF's price was last updated on Aug 27, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AAVXF's recent stock price performance?
Abivax S.A. (AAVXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead drug candidate (ABX464) in Phase II trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AAVXF overvalued or undervalued right now?
Abivax S.A. (AAVXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AAVXF before investing?
Before investing in Abivax S.A. (AAVXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AAVXF to a portfolio?
Key strength of Abivax S.A. (AAVXF): Promising lead drug candidate (ABX464) in Phase II trials. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of AAVXF?
Yes, most major brokerages offer fractional shares of Abivax S.A. (AAVXF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.